Zealand Pharma As Stock Total Debt

ZEAL Stock  DKK 681.50  16.50  2.36%   
Zealand Pharma AS fundamentals help investors to digest information that contributes to Zealand Pharma's financial success or failures. It also enables traders to predict the movement of Zealand Stock. The fundamental analysis module provides a way to measure Zealand Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zealand Pharma stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Zealand Total Debt Analysis

Zealand Pharma's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

 = 

Bonds

+

Notes

More About Total Debt | All Equity Analysis

Current Zealand Pharma Total Debt

    
  647.91 M  
Most of Zealand Pharma's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zealand Pharma AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Competition

Based on the latest financial disclosure, Zealand Pharma AS has a Total Debt of 647.91 M. This is 76.45% lower than that of the Healthcare sector and 99.49% higher than that of the Biotechnology industry. The total debt for all Denmark stocks is 87.81% higher than that of the company.

Zealand Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zealand Pharma's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zealand Pharma could also be used in its relative valuation, which is a method of valuing Zealand Pharma by comparing valuation metrics of similar companies.
Zealand Pharma is currently under evaluation in total debt category among related companies.

Zealand Fundamentals

About Zealand Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Zealand Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zealand Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zealand Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Zealand Pharma AS, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 360 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zealand Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zealand Pharma's short interest history, or implied volatility extrapolated from Zealand Pharma options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Zealand Pharma Piotroski F Score and Zealand Pharma Altman Z Score analysis.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Zealand Stock analysis

When running Zealand Pharma's price analysis, check to measure Zealand Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zealand Pharma is operating at the current time. Most of Zealand Pharma's value examination focuses on studying past and present price action to predict the probability of Zealand Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zealand Pharma's price. Additionally, you may evaluate how the addition of Zealand Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Fundamental Analysis
View fundamental data based on most recent published financial statements
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Money Managers
Screen money managers from public funds and ETFs managed around the world
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Please note, there is a significant difference between Zealand Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zealand Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zealand Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.